Cite
HARVARD Citation
Harshman, L. et al. (2020). Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). Prostate. 80 (16), pp. 1429-1437. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Harshman, L. et al. (2020). Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). Prostate. 80 (16), pp. 1429-1437. [Online].